Nippon India Pharma Fund - Direct Plan - Growth Plan
NAV: ₹ 309.7 as on 25-01-2022
Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Kinjal Desai. The fund could potentially beat inflation in the long-run.
1) Nippon India Pharma Fund - Direct Plan - Growth Plan has a NAV of 309.6557 as on 27-Jan-2022.
2) Nippon India Pharma Fund - Direct Plan - Growth Plan has 5397 Cr worth of assets under management (AUM) as on 27-Jan-2022 and is more than category average.
3) The fund has an expense ratio 1.03 %.
Fund Overview
Expense ratio | 1.03% | |
Benchmark | S&P BSE Healthcare PR | |
AUM | ₹5397 Cr | |
Inception Date | 1 January, 2013 | |
Min Lumpsum/SIP | ₹5000/₹100 | |
Exit Load | 1% | |
Lock In | No Lock-in | |
TurnOver | 55.36% |
Fund Distribution
| Health | 100% |
Top Holdings
Fund Highlights
About the fund
Fund Allocations
AUM size ₹5397 Cr
Expense Ratio 1.03%
Sailesh Raj Bhan is MBA (Finance); CFA
19 Years experience
Kinjal Desai is Masters in Economics from Warwick University, UK; CFA Level 1
10 Years experience
AMC details
Similar Funds
UTI Healthcare Fund-Growth Option- Direct
24.3% (3 Yrs)
DSP Healthcare Fund Direct Growth
31.54% (3 Yrs)
Mirae Asset Healthcare Fund Direct Growth
31.35% (3 Yrs)
SBI Healthcare Opportunities Fund Direct Growth
23.38% (3 Yrs)
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
27.5% (3 Yrs)
Frequently Asked Questions